This study also aimed to investigate if MAP17-expressing cells have a higher NAD pool, and if the depletion of this pool by Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors could sensitize cells to classic chemotherapy in pancreatic tumor xenografts. Here, NAMPT is linked to pancreatic neoplasm.